506. Resistance Analyses from the Remdesivir Phase 3 REDPINE Study in Participants with Severely Reduced Kidney Function Who Were Hospitalized for COVID-19

BACKGROUND: Remdesivir (RDV) is a broad-spectrum nucleotide analog prodrug approved for the treatment of COVID-19 in nonhospitalized and hospitalized adult and pediatric patients with clinical benefit demonstrated in multiple Phase 3 trials. Here we present SARS-CoV-2 resistance analyses from the Ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreatta, Kristen, Li, Jiani, Rodriguez, Lauren, Han, Dong, Xu, Simin, Perry, Jason K, Koullias, Yiannis, Hyland, Robert H, Hedskog, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678162/
http://dx.doi.org/10.1093/ofid/ofad500.575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678162/
http://dx.doi.org/10.1093/ofid/ofad500.575

Ejemplares similares